New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
10:47 EDTJNJ, ENREnergizer says not commenting on whether it would look at buying J&J unit
Energizer (ENR) said on its Q1 earnings conference call that it is not commenting on whether it would look at buying Johnson & Johnson's (JNJ) feminine hygiene unit.
News For ENR;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 19, 2014
09:04 EDTJNJJohnson & Johnson submits NDA for three-month paliperidone palmitate
Janssen Research & Development, a Johnson & Johnson company, announced the submission of a New Drug Application, or NDA, for three-month atypical antipsychotic paliperidone palmitate to the FDA. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. If approved, it will be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule.
06:30 EDTJNJJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
06:14 EDTENREnergizer initiated with a Neutral at BTIG
Subscribe for More Information
November 17, 2014
07:16 EDTJNJMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
16:21 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
14:53 EDTJNJCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
10:00 EDTENROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:07 EDTENREnergizer downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded Energizer to Market Perform citing the recent rally in shares. Wells believes the Duracell sale prices suggests a lower, not higher valuation for shares. It sees a balanced risk/reward as current levels and keeps a $132-$137 price target range for Energizer.
06:13 EDTENREnergizer price target raised to $152 from $134 at Citigroup
Subscribe for More Information
November 13, 2014
16:28 EDTJNJGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
11:54 EDTJNJJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:44 EDTJNJMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
09:47 EDTENREnergizer up 4% to $129.81 after Berkshire buys peer Duracell
Subscribe for More Information
November 12, 2014
08:14 EDTENREnergizer sees FY15 total organic net sales to be flat
Subscribe for More Information
08:13 EDTENREnergizer: Q4 restructuring savings increased $32M vs prior quarter
Restructuring savings in the fourth fiscal quarter increased approximately $32M versus the prior year quarter. The primary impacts of savings were reflected in improved gross margin in Household Products and lower overhead expenses. Project-to-date savings total approximately $255M. The company expects to achieve $300M of savings prior to the anticipated closing of the planned spin-off transaction. Estimated total project savings have been increased to $330M through fiscal 2016. Restructuring related charges for the fourth fiscal quarter were $21.8M. Total project-to-date costs are approximately $260M. Total project restructuring costs are projected to be approximately $350M. As announced on April 30, 2014, the company is pursuing a plan to spin-off the Household Products business and thereby create two independent, publicly traded companies. As a result, the company is incurring incremental costs to evaluate, plan and execute the transaction. For the fourth fiscal 2014 quarter, $37.7M of pre-tax charges were incurred. Total spin-off transaction costs have totaled approximately $45M in fiscal 2014. The company will incur additional costs to execute the transaction and expects these costs to be material.
08:12 EDTENREnergizer reports Q4 Personal Care net sales up 10.5% to $654.7M
Reports Q4 Personal Care organic net sales down 0.6%; Reports Q4 Household Products net sales up 2.8% to $486.7M; Reports Q4 Household Products organic net sales up 4%.
08:11 EDTENREnergizer expects to continue positive momentum in restructuring efforts in 2015
Subscribe for More Information
08:11 EDTENREnergizer reports Q4 adjusted EPS $1.87, consensus $1.61
Subscribe for More Information
November 11, 2014
15:25 EDTENRNotable companies reporting before tomorrow's open
Subscribe for More Information
November 10, 2014
07:44 EDTJNJJohnson & Johnson looks for acquisitions to help expand in China, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use